Logo

Andy Watson, Anthony Scarpello

Feb 19, 2019

Empire Genomics has appointed Andy Watson as CEO and Anthony Scarpello as chief commercialization officer. Watson was previously CEO at Genturi, a genomics technology startup. He was also chief commercial officer at RainDance Technologies, which was acquired by Bio-Rad Laboratories. Prior to Raindance, he was the vice president of SOLiD sequencing product management at Life Technologies, now part of Thermo Fisher Scientific. He also previously led the capillary electrophoresis sequencing business for Applied Biosystems, which became part of Life Technologies.

Scarpello was promoted from vice president of sales and business development to CCO. He joined Empire Genomics in 2009, and previously held numerous senior management roles with Enzo Life Sciences.

Breaking News
The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.